Bristol-Myers Squibb Co (BUE:BMY) Beneish M-Score: -2.73 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:BMY Bristol-Myers Squibb Co BUE:BMY
56 GF Score
Price ARS30,980.00
GF Value ARS28,025.90
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Bristol-Myers Squibb Co Beneish M-Score?

Bristol-Myers Squibb Co BUE:BMY +3.06% 56 Beneish M-Score is -2.73 as of Jul. 14, 2026. GuruFocus rates BUE:BMY with a GF Score™ of 56/100 and a GF Value™ of ARS28,025.90 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 911 Drug Manufacturers companies, Bristol-Myers Squibb Co ranks better than 70.25% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.73 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Bristol-Myers Squibb Co's Beneish M-Score or its related term are showing as below:

BUE:BMY' s Beneish M-Score Range Over the Past 10 Years
Min: -3.34   Med: -2.81   Max: -1.66
Current: -2.73

During the past 13 years, the highest Beneish M-Score of Bristol-Myers Squibb Co was -1.66. The lowest was -3.34. And the median was -2.81.


Bristol-Myers Squibb Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Bristol-Myers Squibb Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co Beneish M-Score Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.81 -2.70 -2.79 -3.15 -2.60

Bristol-Myers Squibb Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.87 -2.90 -2.85 -2.60 -2.73

BUE:BMY vs PFE, GILD, AMGN: Beneish M-Score Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bristol-Myers Squibb Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Beneish M-Score falls into.


BUE:BMY
56GF Score
Bristol-Myers Squibb Co BUE:BMY
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bristol-Myers Squibb Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Bristol-Myers Squibb Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7751+0.528 * 1.0002+0.404 * 1.0059+0.892 * 1.4019+0.115 * 1.6987
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.946+4.679 * -0.041198-0.327 * 0.9419
=-2.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ARS16,894,995 Mil.
Revenue was 16064437.845 + 18147966.82 + 16597627.579 + 14566164.21 = ARS65,376,196 Mil.
Gross Profit was 11281041.391 + 12201216.435 + 11932854.978 + 10562813.838 = ARS45,977,927 Mil.
Total Current Assets was ARS38,043,452 Mil.
Total Assets was ARS120,914,642 Mil.
Property, Plant and Equipment(Net PPE) was ARS12,845,678 Mil.
Depreciation, Depletion and Amortization(DDA) was ARS4,821,906 Mil.
Selling, General, & Admin. Expense(SGA) was ARS9,889,874 Mil.
Total Current Liabilities was ARS26,787,579 Mil.
Long-Term Debt & Capital Lease Obligation was ARS61,413,721 Mil.
Net Income was 3743102.107 + 1577768.53 + 2988985.297 + 1555275.5 = ARS9,865,131 Mil.
Non Operating Income was 397101.606 + -1319403.49 + -59752.546 + -1801032.774 = ARS-2,783,087 Mil.
Cash Flow from Operations was 1543662.58 + 2865239.263 + 8570416.27 + 4650392.47 = ARS17,629,711 Mil.
Total Receivables was ARS15,549,215 Mil.
Revenue was 11940679.735 + 12465420.125 + 11303345.503 + 10925995.344 = ARS46,635,441 Mil.
Gross Profit was 8707389.704 + 7605300.076 + 8492717.127 + 8000396.886 = ARS32,805,804 Mil.
Total Current Assets was ARS32,815,815 Mil.
Total Assets was ARS98,530,596 Mil.
Property, Plant and Equipment(Net PPE) was ARS8,984,559 Mil.
Depreciation, Depletion and Amortization(DDA) was ARS7,766,043 Mil.
Selling, General, & Admin. Expense(SGA) was ARS7,457,328 Mil.
Total Current Liabilities was ARS25,659,509 Mil.
Long-Term Debt & Capital Lease Obligation was ARS50,650,613 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(16894995.429 / 65376196.454) / (15549214.768 / 46635440.707)
=0.258427 / 0.333421
=0.7751

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(32805803.793 / 46635440.707) / (45977926.642 / 65376196.454)
=0.703452 / 0.703282
=1.0002

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (38043452.424 + 12845677.647) / 120914642.451) / (1 - (32815815.042 + 8984559.308) / 98530596.006)
=0.579132 / 0.575762
=1.0059

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=65376196.454 / 46635440.707
=1.4019

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(7766043.259 / (7766043.259 + 8984559.308)) / (4821905.636 / (4821905.636 + 12845677.647))
=0.463628 / 0.272924
=1.6987

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(9889874.465 / 65376196.454) / (7457327.923 / 46635440.707)
=0.151276 / 0.159907
=0.946

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((61413720.867 + 26787579.445) / 120914642.451) / ((50650613.003 + 25659509.081) / 98530596.006)
=0.729451 / 0.774481
=0.9419

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(9865131.434 - -2783087.204 - 17629710.583) / 120914642.451
=-0.041198

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Bristol-Myers Squibb Co has a M-score of -2.41 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.73 mean?
Bristol-Myers Squibb Co (BUE:BMY) has a Beneish M-Score of -2.73 as of Jul. 14, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Bristol-Myers Squibb Co and its competitors. According to the industry distribution chart, Bristol-Myers Squibb Co ranks #271 out of 911 companies in the Drug Manufacturers industry, placing it in the top 29.7%.
Is Bristol-Myers Squibb Co's Beneish M-Score too high?
Bristol-Myers Squibb Co's current Beneish M-Score is -2.73. Based on the distribution chart, Bristol-Myers Squibb Co ranks #271 out of 911 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bristol-Myers Squibb Co has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's Beneish M-Score compare to PFE and GILD?
According to the Drug Manufacturers industry distribution chart, Bristol-Myers Squibb Co ranks #271 out of 911 companies for Beneish M-Score. This puts Bristol-Myers Squibb Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current Beneish M-Score is -2.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (BUE:BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is ARS28,025.90, compared to a current price of ARS30,980.00 — trading 10.5% above its estimated fair value. The current Beneish M-Score is -2.73. Bristol-Myers Squibb Co's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Bristol-Myers Squibb Co (BUE:BMY), the current Beneish M-Score is -2.73 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bristol-Myers Squibb Co (BUE:BMY) Overvalued in 2026?

Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued. The current stock price of ARS30,980.00 is trading 10.5% above its estimated GF Value™ of ARS28,025.90. GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.

Key valuation signals for BUE:BMY:

  • Beneish M-Score: -2.73
  • GF Value™: ARS28,025.90 vs. price of ARS30,980.00 (10.5% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the BUE:BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bristol-Myers Squibb Co Business Description

Address Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
56GF Score

Get the complete analysis for BUE:BMY

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS30,980.00
Price
ARS28,025.90
GF Value